

184. [Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival](#). Sooman L, Lennartsson J, Gullbo J, Bergqvist M, Tsakonas G, Johansson F, Edqvist PH, Pontén F, Jaiswal A, Navani S, **Alafuzoff I**, Popova S, Blomquist E, Ekman S. *Med Oncol*. 2013 Sep;30(3):638.
183. [Perfusion and diffusion MRI combined with \(11\)C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas](#). Berntsson SG, Falk A, Savitcheva I, Godau A, Zetterling M, Hesselager G, **Alafuzoff I**, Larsson EM, Smits A. *J Neurooncol*. 2013 Sep;114(2):241-9..
182. [Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study](#). Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A, **Alafuzoff I**. *J Neuropathol Exp Neurol*. 2013 Jun;72(6):452-61.
181. [Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus](#). Koivisto AM, **Alafuzoff I**, Savolainen S, Sutela A, Rummukainen J, Kurki M, Jääskeläinen JE, Soininen H, Rinne J, Leinonen V; Kuopio NPH Registry (www.uef.fi/nph). *Neurosurgery*. 2013 Jan;72(1):1-8;discussion 8
180. [APOE4 predicts amyloid- \$\beta\$ in cortical brain biopsy but not idiopathic normal pressure hydrocephalus](#). Pyykkö OT, Helisalmi S, Koivisto AM, Mölsä JA, Rummukainen J, Nerg O, **Alafuzoff I**, Savolainen S, Soininen H, Jääskeläinen JE, Rinne J, Leinonen V, Hiltunen M. *J Neurol Neurosurg Psychiatry*. 2012 Nov;83(11):1119-24.
179. [GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients](#). Kämäläinen A, Viswanathan J, Natunen T, Helisalmi S, Kauppinen T, Pikkarainen M, Pursiheimo JP, **Alafuzoff I**, Kivipelto M, Haapasalo A, Soininen H, Herukka SK, Hiltunen M. *J Alzheimers Dis*. 2013;33(1):23-7.
178. [Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGF \$\beta\$ 2 in vascular abnormalization](#). Dieterich LC, Mellberg S, Langenkamp E, Zhang L, Zieba A, Salomäki H, Teichert M, Huang H, Edqvist PH, Kraus T, Augustin HG, Olofsson T, Larsson E, Söderberg O, Molema G, Pontén F, Georgii-Hemming P, **Alafuzoff I**, Dimberg A. *J Pathol*. 2012 Nov;228(3):378-90.
177. [The need to unify neuropathological assessments of vascular alterations in the ageing brain: multicentre survey by the BrainNet Europe consortium](#). **Alafuzoff I**, Gelpi E, Al-Sarraj S, Arzberger T, Attems J, Bodi I, Bogdanovic N, Budka H, Bugiani O, Englund E, Ferrer I, Gentleman S, Giaccone G, Graeber MB, Hortobagyi T, Höftberger R, Ironside JW, Jellinger K, Kavantzias N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Rozemuller A, Seilhean D, Streichenberger N, Thal DR, Wharton SB, Kretschmar H. *Exp Gerontol*. 2012 Nov;47(11):825-33.
176. [Alzheimer's disease-related lesions](#). **Alafuzoff I**. *J Alzheimers Dis*. 2013;33 Suppl 1:S173-9. Review.

175. [GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome.](#) Smits A, Jin Z, Elsir T, Pedder H, Nistér M, **Alafuzoff I**, Dimberg A, Edqvist PH, Pontén F, Aronica E, Birnir B. PLoS One. 2012;7(5):e37041.
174. [CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.](#) Seppälä TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykkö OT, Helisalmi S, **Alafuzoff I**, Hiltunen M, Jääskeläinen JE, Rinne J, Soininen H, Leinonen V, Herukka SK. Neurology. 2012 May 15;78(20):1568-75.
173. [Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.](#) Nelson PT, **Alafuzoff I**, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. J Neuropathol Exp Neurol. 2012 May;71(5):362-81.
172. [Neuropathology of the hippocampus in FTL-D-Tau with Pick bodies: A study of the BrainNet Europe Consortium.](#) Kovacs GG, Rozemuller AJ, van Swieten JC, Gelpi E, Majtenyi K, Al-Sarraj S, Troakes C, Bódi I, King A, Hortobágyi T, Esiri MM, Ansorge O, Giaccone G, Ferrer I, Arzberger T, Bogdanovic N, Nilsson T, Leisner I, **Alafuzoff I**, Ironside JW, Kretschmar H, Budka H. Neuropathol Appl Neurobiol. 2012 Apr 4. doi: 10.1111/j.1365-2990.2012.01272.x. [Epub ahead of print]
171. [An antibody with high reactivity for disease-associated \$\alpha\$ -synuclein reveals extensive brain pathology.](#) Kovacs GG, Wagner U, Dumont B, Pikkariainen M, Osman AA, Streichenberger N, Leisner I, Verchère J, Baron T, **Alafuzoff I**, Budka H, Perret-Liaudet A, Lachmann I. Acta Neuropathol. 2012 Jul;124(1):37-50.
170. [Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus.](#) Leinonen V, Koivisto AM, **Alafuzoff I**, Pyykkö OT, Rummukainen J, von Und Zu Fraunberg M, Jääskeläinen JE, Soininen H, Rinne J, Savolainen S. Neurodegener Dis. 2012;10(1-4):166-9. doi: 10.1159/000335155. Epub 2012 Feb 10.
169. [Divergent clinical and neuropathological phenotype in a Gerstmann-Sträussler-Scheinker P102L family.](#) Popova SN, Tarvainen I, Capellari S, Parchi P, Hannikainen P, Pirinen E, Haapasalo H, **Alafuzoff I**. Acta Neurol Scand. 2012 Nov;126(5):315-23.
168. [Hyperphosphorylated tau in young and middle-aged subjects.](#) Elobeid A, Soininen H, **Alafuzoff I**. Acta Neuropathol. 2012 Jan;123(1):97-104.
167. [Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer's disease.](#) Salminen A, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H, **Alafuzoff I**. Prog Neurobiol. 2012 Jan;96(1):87-95.
166. [Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling.](#) Nord H, Pfeifer S, Nilsson P, Sandgren J, Popova S, Strömberg B, **Alafuzoff I**, Nistér M, Díaz de Ståhl T. J Neurooncol. 2012 Mar;107(1):37-49.

165. [Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12](#). Pölajeva J, Sjösten AM, Lager N, Kastemar M, Waern I, **Alafuzoff I**, Smits A, Westermarck B, Pejler G, Uhrbom L, Tchougounova E. PLoS One. 2011;6(9):e25222. doi: 10.1371/journal.pone.0025222. Epub 2011 Sep 19.

164. [Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature](#). Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Sutela A, Vanninen R, Jääskeläinen JE, Soininen H, **Alafuzoff I**. Neuropathol Appl Neurobiol. 2012 Feb;38(1):72-86. doi: 10.1111/j.1365-2990.2011.01195.x. Review.

163. [Distribution and pattern of pathology in subjects with familial or sporadic late-onset cerebellar ataxia as assessed by p62/sequestosome immunohistochemistry](#). Pikkarainen M, Hartikainen P, Soininen H, **Alafuzoff I**. Cerebellum. 2011 Dec;10(4):720-31.

162. [Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma \(FUS\) positive inclusions](#). Hartikainen PH, Pikkarainen M, Hänninen T, Soininen H, **Alafuzoff I**. Neuropathology. 2012 Feb;32(1):60-8.

161. [New lexicon and criteria for the diagnosis of Alzheimer's disease](#). Giaccone G, Arzberger T, **Alafuzoff I**, Al-Sarraj S, Budka H, Duyckaerts C, Falkai P, Ferrer I, Ironside JW, Kovács GG, Meyronet D, Parchi P, Patsouris E, Revesz T, Riederer P, Rozemuller A, Schmitt A, Winblad B, Kretschmar H; BrainNet Europe consortium. Lancet Neurol. 2011 Apr;10(4):298-9; author reply 300-1.

160. [TAR-DNA binding protein-43 and alterations in the hippocampus](#). Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A, **Alafuzoff I**. J Neural Transm. 2011 May;118(5):683-9.

2010

159. [Long-term epilepsy surgery outcomes in patients with MRI-negative temporal lobe epilepsy](#). Immonen A, Jutila L, Muraja-Murro A, Mervaala E, Äikiä M, Lamusuo S, Kuikka J, Vanninen E, **Alafuzoff I**, Ikonen A, Vanninen R, Vapalahti M, Kälviäinen R. Epilepsia. 2010 Nov;51(11):2260-9.

158. [Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease](#). Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Tamminen JN, Tillgren T, Vainikka S, Pyykkö OT, Mölsä J, Fraunberg M, Pirttilä T, Jääskeläinen JE, Soininen H, Rinne J, **Alafuzoff I**. Ann Neurol. 2010 Oct;68(4):446-53.

157. [Neuronal collagen XVII is localized to lipofuscin granules](#). Seppänen A, Miettinen R, **Alafuzoff I**. Neuroreport. 2010 Dec 8;21(17):1090-4.

156. [Claudins 1, 11 and twist in meningiomas](#). Soini Y, Rauramaa T, **Alafuzoff I**, Sandell PJ, Kärjä V. Histopathology. 2010 May;56(6):821-4.

155. [Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain](#). Aho L, Pikkarainen M, Hiltunen M, Leinonen V, **Alafuzoff I**. J Alzheimers Dis. 2010;20(4):1015-28.

154. [Malignant giant cell tumor in the posterior fossa of a neonate](#). Karamanakos PN, Jaaskelainen JE, **Alafuzoff I**, Pirinen E, Vanninen R, Silvennoinen S, Sankilampi U, Immonen A. *J Neurosurg Pediatr*. 2010 Mar;5(3):277-82.

153. [Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions](#). Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White CL 3rd, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, Lopez de Munain A, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IR, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, **Alafuzoff I**, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM. *Nat Genet*. 2010 Mar;42(3):234-9. doi: 10.1038/ng.536

152. [Analysis of human tau in cerebrospinal fluid](#). Hanisch K, Soininen H, **Alafuzoff I**, Hoffmann R. *J Proteome Res*. 2010 Mar 5;9(3):1476-82.

151. [Cardiovascular diseases and hippocampal infarcts](#). Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A, Parkkinen L, **Alafuzoff I**. *Hippocampus*. 2011 Mar;21(3):281-7.

150. [The effect of prolonged fixation time on immunohistochemical staining of common neurodegenerative disease markers](#). Pikkarainen M, Martikainen P, **Alafuzoff I**. *J Neuropathol Exp Neurol*. 2010 Jan;69(1):40-52

149. [Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update](#). Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, **Alafuzoff I**, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM. *Acta Neuropathol*. 2010 Jan;119(1):1-4.

148. [Brain pathology in three subjects from the same pedigree with presenilin-1 \(PSEN1\) P264L mutation](#). Martikainen P, Pikkarainen M, Pöntynen K, Hiltunen M, Lehtovirta M, Tuisku S, Soininen H, **Alafuzoff I**. *Neuropathol Appl Neurobiol*. 2010 Feb;36(1):41-54. **2009**

147. [Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease](#). Singer D, Soininen H, **Alafuzoff I**, Hoffmann R. *Anal Bioanal Chem*. 2009 Dec;395(7):2263-7. doi: 10.1007/s00216-009-3208-8. Epub 2009 Oct 11. Erratum in: *Anal Bioanal Chem*. 2009 Dec;395(7):2423.

146. [Does protein expression predict recurrence of benign World Health Organization grade I meningioma?](#) Kärjä V, Sandell PJ, Kauppinen T, **Alafuzoff I**. Hum Pathol. 2010 Feb;41(2):199-207.
145. [Ubiquitinated p62-positive, TDP-43-negative inclusions in cerebellum in frontotemporal lobar degeneration with TAR DNA binding protein 43.](#) Pikkarainen M, Hartikainen P, **Alafuzoff I**. Neuropathology. 2010 Apr;30(2):197-9.
144. [Tryptophan is a marker of human postmortem brain tissue quality.](#) Grünblatt E, Monoranu CM, Apfelbacher M, Keller D, Michel TM, **Alafuzoff I**, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, McLean C, Halliday GM, Harper C, Deckert J, Roggendorf W, Riederer P. J Neurochem. 2009 Sep;110(5):1400-8.
143. [pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium.](#) Monoranu CM, Apfelbacher M, Grünblatt E, Puppe B, **Alafuzoff I**, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, Halliday G, Kril J, Harper C, McLean C, Riederer P, Roggendorf W. Neuropathol Appl Neurobiol. 2009 Jun;35(3):329-37.
142. [Hyperphosphorylated tau in the occipital cortex in aged nondemented subjects.](#) Pikkarainen M, Kauppinen T, **Alafuzoff I**. J Neuropathol Exp Neurol. 2009 Jun;68(6):653-60.
141. [Heavy alcohol consumption and neuropathological lesions: a post-mortem human study.](#) Aho L, Karkola K, Juusela J, **Alafuzoff I**. J Neurosci Res. 2009 Sep;87(12):2786-92.
140. [Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium.](#) **Alafuzoff I**, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzias N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenberger N, Thal DR, Kretschmar H. Acta Neuropathol. 2009 Jun;117(6):635-52.
139. [Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.](#) Tapiola T, **Alafuzoff I**, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T. Arch Neurol. 2009 Mar;66(3):382-9.
138. [Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium.](#) **Alafuzoff I**, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S, Bodi I, Boluda S, Bugiani O, Duyckaerts C, Gelpi E, Gentleman S, Giaccone G, Graeber M, Hortobagyi T, Höftberger R, Ince P, Ironside JW, Kavantzias N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Nilsson T, Parchi P, Patsouris E, Pikkarainen M, Revesz T, Rozemuller A, Seilhean D, Schulz-Schaeffer W, Streichenberger N, Wharton SB, Kretschmar H. Acta Neuropathol. 2009 Mar;117(3):309-20.
137. [Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.](#) Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, **Alafuzoff I**, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM. Acta Neuropathol. 2009 Jan;117(1):15-8.

136. [Expression of collagen XVII and ubiquitin-binding protein p62 in motor neuron disease.](#) Seppänen A, Pikkarainen M, Hartikainen P, Hofmann SC, Majamaa K, **Alafuzoff I**. Brain Res. 2009 Jan 9;1247:171-7.

2008

135. [Mixed brain pathologies in dementia: the BrainNet Europe consortium experience.](#) Kovacs GG, **Alafuzoff I**, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S, Ferrer I, Gelpi E, Kövari V, Kretschmar H, Nagy Z, Parchi P, Seilhean D, Soininen H, Troakes C, Budka H. Dement Geriatr Cogn Disord. 2008;26(4):343-50.

134. [The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.](#) Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, **Alafuzoff I**, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13145-50.

133. [Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.](#) Leinonen V, **Alafuzoff I**, Aalto S, Suotunen T, Savolainen S, Nägren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO. Arch Neurol. 2008 Oct;65(10):1304-9.

132. [Cerebral amyloid angiopathy, hemorrhages and superficial siderosis.](#) **Alafuzoff I**. Stroke. 2008 Oct;39(10):2699-700.

131. [Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects.](#) Aho L, Parkkinen L, Pirttilä T, **Alafuzoff I**. Dement Geriatr Cogn Disord. 2008;25(5):423-32.

130. [Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry.](#) Pikkarainen M, Hartikainen P, **Alafuzoff I**. J Neuropathol Exp Neurol. 2008 Apr;67(4):280-98.

129. [Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium.](#) **Alafuzoff I**, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Ince P, Kamphorst W, King A, Korkolopoulou P, Kovács GG, Larionov S, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Tagliavini F, Stadelmann C, Streichenberger N, Thal DR, Wharton SB, Kretschmar H. Brain Pathol. 2008 Oct;18(4):484-96.

128. [Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium.](#) Bell JE, **Alafuzoff I**, Al-Sarraj S, Arzberger T, Bogdanovic N, Budka H, Dexter DT, Falkai P, Ferrer I, Gelpi E, Gentleman SM, Giaccone G, Huitinga I, Ironside JW, Klioueva N, Kovacs GG, Meyronet D, Palkovits M, Parchi P, Patsouris E, Reynolds R, Riederer P, Roggendorf W, Seilhean D, Schmitt A, Schmitz P, Streichenberger N, Schwalber A, Kretschmar H. Acta Neuropathol. 2008 May;115(5):497-507.

127. [Beta-amyloid deposition in brains of subjects with diabetes.](#) **Alafuzoff I**, Aho L, Helisalmi S, Mannermaa A, Soininen H. Neuropathol Appl Neurobiol. 2009 Feb;35(1):60-8.

126. [Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium.](#) **Alafuzoff I**, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J, Bodi I, Budka H, Capetillo-Zarate E, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kavantzias N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Stadelmann C, Streichenberger N, Tagliavini F, Kretzschmar H. *Acta Neuropathol.* 2008 May;115(5):533-46.

125. [Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance.](#) Parkkinen L, Pirttilä T, **Alafuzoff I**. *Acta Neuropathol.* 2008 Apr;115(4):399-407.

124. [Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms.](#) Parkkinen L, Hartikainen P, **Alafuzoff I**. *Clin Neuropathol.* 2007 Nov-Dec;26(6):276-83.

123. [Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium.](#) **Alafuzoff I**, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovács GG, Larionov S, Meyronet D, Monoranu C, Morris J, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Kretzschmar H; BrainNet Europe Consortium. *J Neuropathol Exp Neurol.* 2008 Feb;67(2):125-43.

122. [Use of p62/SQSTM1 antibodies for neuropathological diagnosis.](#) Kuusisto E, Kauppinen T, **Alafuzoff I**. *Neuropathol Appl Neurobiol.* 2008 Apr;34(2):169-80.

2007

121. [Integration of expression profiles and genetic mapping data to identify candidate genes in intracranial aneurysm.](#) Weinsheimer S, Lenk GM, van der Voet M, Land S, Ronkainen A, **Alafuzoff I**, Kuivaniemi H, Tromp G. *Physiol Genomics.* 2007 Dec 19;32(1):45-57.

120. [Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients.](#) Ojala J, **Alafuzoff I**, Herukka SK, van Groen T, Tanila H, Pirttilä T. *Neurobiol Aging.* 2009 Feb;30(2):198-209..

119. [Increased expression of caspase 2 in experimental and human temporal lobe epilepsy.](#) Narkilahti S, Jutila L, **Alafuzoff I**, Karkola K, Paljärvi L, Immonen A, Vapalahti M, Mervaala E, Kälviäinen R, Pitkänen A. *Neuromolecular Med.* 2007;9(2):129-44.

118. [No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease.](#) Buerger K, **Alafuzoff I**, Ewers M, Pirttilä T, Zinkowski R, Hampel H. *Brain.* 2007 Oct;130(Pt 10):e82. Epub 2007 Jul 5. No abstract available.

117. [Distribution of collagen XVII in the human brain.](#) Seppänen A, Suuronen T, Hofmann SC, Majamaa K, **Alafuzoff I**. *Brain Res.* 2007 Jul 16;1158:50-6.

116. [How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II.](#) Schmitt A, Bauer M, Heinsen H, Feiden W; Consortium of Brainnet Europe II, Falkai P, **Alafuzoff I**, Arzberger T, Al-Sarraj S, Bell JE, Bogdanovic N, Brück W, Budka H, Ferrer I, Giaccone G, Kovacs GG, Meyronet D, Palkovits M, Parchi P, Patsouris E, Ravid R, Reynolds

R, Riederer P, Roggendorf W, Schwalber A, Seilhean D, Kretschmar H.J Neural Transm. 2007;114(5):527-37.

2006

115. [Beta-amyloid aggregation in human brains with cerebrovascular lesions](#). Aho L, Jolkkonen J, **Alafuzoff I**. Stroke. 2006 Dec;37(12):2940-5.

114. [CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease](#). Buerger K, Ewers M, Pirttilä T, Zinkowski R, **Alafuzoff I**, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. Brain. 2006 Nov;129(Pt 11):3035-41.

113. [Cerebroretinal microangiopathy with calcifications and cysts](#). Linnankivi T, Valanne L, Paetau A, **Alafuzoff I**, Hakumäki JM, Kivelä T, Lönnqvist T, Mäkitie O, Pääkkönen L, Vainionpää L, Vanninen R, Herva R, Pihko H. Neurology. 2006 Oct 24;67(8):1437-43.

112. [Human postmortem brain tissue and 2-mm tissue microarrays](#). Kauppinen T, Martikainen P, **Alafuzoff I**. Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):353-9.

111. [Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry](#). Braak H, **Alafuzoff I**, Arzberger T, Kretschmar H, Del Tredici K. Acta Neuropathol. 2006 Oct;112(4):389-404.

110. [Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium](#). **Alafuzoff I**, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Bugiani O, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Hauw JJ, Kamphorst W, King A, Kopp N, Korkolopoulou P, Kovács GG, Meyronet D, Parchi P, Patsouris E, Preusser M, Ravid R, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Kretschmar H.J Neuropathol Exp Neurol. 2006 Aug;65(8):740-57.

109. [Human brain tissue microarrays as a platform to investigate diseases of the nervous system](#). Martikainen P, Louhelainen AM, Kauppinen T, **Alafuzoff I**. Brain Res. 2006 May 17;1089(1):33-43.

108. [Case report: central neurocytoma with concomitant cerebral involvement by acute lymphatic leukemia](#). Böhm J, Immonen A, Riikonen P, Vanninen R, **Alafuzoff I**. Hum Pathol. 2006 Apr;37(4):488-92.

107. [Postmortem examination of vascular lesions in cognitive impairment: a survey among neuropathological services](#). Pantoni L, Sarti C, **Alafuzoff I**, Jellinger K, Munoz DG, Ogata J, Palumbo V. Stroke. 2006 Apr;37(4):1005-9.

106. [Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains](#). Zhou XW, Li X, Bjorkdahl C, Sjogren MJ, **Alafuzoff I**, Soininen H, Grundke-Iqbal I, Iqbal K, Winblad B, Pei JJ. Neurobiol Dis. 2006 Jun;22(3):657-68.

105. [Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy](#). Kärjä V, **Alafuzoff I**. Clin Neuropathol. 2006 Jan-Feb;25(1):37-43.

104. [Collagen XVII is expressed in human CNS neurons.](#) Seppänen A, Autio-Harmanen H, **Alafuzoff I**, Särkioja T, Veijola J, Hurskainen T, Bruckner-Tuderman L, Tasanen K, Majamaa K. *Matrix Biol.* 2006 Apr;25(3):185-8.

103. [Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.](#) Parkkinen L, Pirttilä T, Tervahauta M, **Alafuzoff I**. *Neuropathology.* 2005 Dec;25(4):304-14.

102. [Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain.](#) Korolainen MA, Goldsteins G, Nyman TA, **Alafuzoff I**, Koistinaho J, Pirttilä T. *Neurobiol Aging.* 2006 Jan;27(1):42-53.

2005

101. [Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.](#) Iqbal K, Flory M, Khatoon S, Soininen H, Pirttilä T, Lehtovirta M, **Alafuzoff I**, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I. *Ann Neurol.* 2005 Nov;58(5):748-57.

100. [Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain.](#) Li X, **Alafuzoff I**, Soininen H, Winblad B, Pei JJ. *FEBS J.* 2005 Aug;272(16):4211-20.

99. [Cystatin C expression is associated with granule cell dispersion in epilepsy.](#) Pirttilä TJ, Manninen A, Jutila L, Nissinen J, Kälviäinen R, Vapalahti M, Immonen A, Paljärvi L, Karkola K, **Alafuzoff I**, Mervaala E, Pitkänen A. *Ann Neurol.* 2005 Aug;58(2):211-23.

98. [Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain.](#) Korolainen MA, Auriola S, Nyman TA, **Alafuzoff I**, Pirttilä T. *Neurobiol Dis.* 2005 Dec;20(3):858-70. Epub 2005 Jun 27.

97. [Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.](#) Parkkinen L, Kauppinen T, Pirttilä T, Autere JM, **Alafuzoff I**. *Ann Neurol.* 2005 Jan;57(1):82-91.

2004

96. [Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients.](#) Helisalmi S, Hiltunen M, Vepsäläinen S, Iivonen S, Mannermaa A, Lehtovirta M, Koivisto AM, **Alafuzoff I**, Soininen H. *J Neurol Neurosurg Psychiatry.* 2004 Dec;75(12):1746-8.

95. [Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain.](#) Li X, An WL, **Alafuzoff I**, Soininen H, Winblad B, Pei JJ. *Neuroreport.* 2004 Oct 5;15(14):2237-40.

94. [Prenatal diagnosis of placenta accreta and percreta with ultrasonography, color Doppler, and magnetic resonance imaging.](#) Taipale P, Orden MR, Berg M, Manninen H, **Alafuzoff I**.

Obstet Gynecol. 2004 Sep;104(3):537-40.

93. [Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach.](#) Kanninen K, Goldsteins G, Auriola S, **Alafuzoff I**, Koistinaho J. Neurosci Lett. 2004 Sep 2;367(2):235-40.

92. [Preoperative clinical evaluation, outline of surgical technique and outcome in temporal lobe epilepsy.](#) Immonen A, Jutila L, Kälviäinen R, Mervaala E, Partanen K, Partanen J, Vanninen R, Ylinen A, **Alafuzoff I**, Paljärvi L, Hurskainen H, Rinne J, Puranen M, Vapalahti M. Adv Tech Stand Neurosurg. 2004;29:87-132. Review.

2003

91. [Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62.](#) Kuusisto E, Parkkinen L, **Alafuzoff I**. J Neuropathol Exp Neurol. 2003 Dec;62(12):1241-53.

90. [Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology.](#) Iivonen S, Helisalmi S, Mannermaa A, **Alafuzoff I**, Lehtovirta M, Soininen H, Hiltunen M. Neurosci Lett. 2003 Dec 4;352(2):146-50.

89. [Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.](#) An WL, Cowburn RF, Li L, Braak H, **Alafuzoff I**, Iqbal K, Iqbal IG, Winblad B, Pei JJ. Am J Pathol. 2003 Aug;163(2):591-607. Erratum in: Am J Pathol. 2003 Dec;163(6):2645.

88. [Brain biopsy prior to treatment of Alzheimer's disease.](#) Holm A, Savolainen S, **Alafuzoff I**. Minim Invasive Neurosurg. 2003 Jun;46(3):161-4.

87. [Reelin-immunoreactive Cajal-Retzius cells: the entorhinal cortex in normal aging and Alzheimer's disease.](#) Riedel A, Miettinen R, Stieler J, Mikkonen M, **Alafuzoff I**, Soininen H, Arendt T. Acta Neuropathol. 2003 Oct;106(4):291-302. Epub 2003 Jun 17.

86. [Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease.](#) Parkkinen L, Soininen H, **Alafuzoff I**. J Neuropathol Exp Neurol. 2003 Apr;62(4):363-7.

85. [Role of protein kinase B in Alzheimer's neurofibrillary pathology.](#) Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, **Alafuzoff I**, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K. Acta Neuropathol. 2003 Apr;105(4):381-92. Epub 2002 Dec 18.

84. [Prenatal diagnosis of holoprosencephaly and ectopia cordis in a twin at 12 weeks' gestation.](#) Taipale PJ, Krista T, **Alafuzoff I**. Ultrasound Obstet Gynecol. 2003 Feb;21(2):198-200. No abstract available.

83. [Absence of association between an intercellular adhesion molecule 1 gene E469K polymorphism and Alzheimer's disease in Finnish patients.](#) Mattila KM, Hiltunen M, Rinne

JO, Mannermaa A, Røyttä M, **Alafuzoff I**, Laippala P, Soininen H, Lehtimäki T. *Neurosci Lett*. 2003 Jan 30;337(1):61-3.

2002

82. [Castleman's disease of the leptomeninges--immunohistochemical findings in 2 cases.](#)

Ropponen KM, Kankkunen JP, Ronkainen A, Vihavainen M, **Alafuzoff I**. *Clin Neuropathol*. 2002 Nov-Dec;21(6):278-83.

81. [Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients.](#)

Juttila L, Immonen A, Mervaala E, Partanen J, Partanen K, Puranen M, Kälviäinen R, **Alafuzoff I**, Hurskainen H, Vapalahti M, Ylinen A. *J Neurol Neurosurg Psychiatry*. 2002 Nov;73(5):486-94.

80. [Proteomic analysis of protein oxidation in Alzheimer's disease brain.](#) Korolainen MA, Goldsteins G, **Alafuzoff I**, Koistinaho J, Pirttilä T. *Electrophoresis*. 2002 Sep;23(19):3428-33.

79. [Molecular genetic analysis of the alpha-synuclein and the parkin gene in Parkinson's disease in Finland.](#) Autere JM, Hiltunen MJ, Mannermaa AJ, Jäkälä PA, Hartikainen PH, Majamaa K, **Alafuzoff I**, Soininen HS. *Eur J Neurol*. 2002 Sep;9(5):479-83.

78. [Interleukin 1 alpha gene polymorphism as a susceptibility factor in Alzheimer's disease and its influence on the extent of histopathological hallmark lesions of Alzheimer's disease.](#)

Pirkanen M, Hiltunen M, Mannermaa A, Iivonen S, Helisalmi S, Lehtovirta M, Koivisto AM, Laakso M, Soininen H, **Alafuzoff I**. *Dement Geriatr Cogn Disord*. 2002;14(3):123-7.

77. [Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs.](#) **Alafuzoff I**, Overmyer M, Helisalmi S, Soininen H. *J Alzheimers Dis*. 2000 Mar;2(1):37-46.

76. [Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease.](#) Iivonen S, Hiltunen M, **Alafuzoff I**, Mannermaa A, Kerokoski P, Puoliväli J, Salminen A, Helisalmi S, Soininen H. *Neuroscience*. 2002;113(2):301-10.

75. [Five-year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test.](#)

Savolainen S, Hurskainen H, Paljärvi L, **Alafuzoff I**, Vapalahti M. *Acta Neurochir (Wien)*. 2002 Jun;144(6):515-23; discussion 523.

74. [Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation.](#) Kuusisto E, Salminen A, **Alafuzoff I**. *Neuropathol Appl Neurobiol*. 2002 Jun;28(3):228-37.

73. [Neurobiology of epileptogenesis in the temporal lobe.](#) Juttila L, Immonen A, Partanen K, Partanen J, Mervaala E, Ylinen A, **Alafuzoff I**, Paljärvi L, Karkola K, Vapalahti M, Pitkänen A. *Adv Tech Stand Neurosurg*. 2002;27:5-22. Review. No abstract available.

2001

72. [Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation](#). Laitinen KS, van Groen T, Tanila H, Venäläinen J, Männistö PT, **Alafuzoff I**. Neuroreport. 2001 Oct 29;12(15):3309-12.
71. [MR volumetry of the entorhinal, perirhinal, and temporopolar cortices in drug-refractory temporal lobe epilepsy](#). Jutila L, Ylinen A, Partanen K, **Alafuzoff I**, Mervaala E, Partanen J, Vapalahti M, Vainio P, Pitkänen A. AJNR Am J Neuroradiol. 2001 Sep;22(8):1490-501.
70. [Alpha-synuclein pathology is highly dependent on the case selection](#). Parkkinen L, Soininen H, Laakso M, **Alafuzoff I**. Neuropathol Appl Neurobiol. 2001 Aug;27(4):314-25.
69. [An association between a subset of Finnish late-onset Alzheimer's disease and alpha2-macroglobulin](#). Pirskanen M, **Alafuzoff I**, Hiltunen M, Mannermaa A, Helisalmi S, Lehtovirta M, Koivisto AM, Laakso M, Soininen H. Neurogenetics. 2001 Jul;3(3):171-2. No abstract available.
68. [Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies](#). Kuusisto E, Salminen A, **Alafuzoff I**. Neuroreport. 2001 Jul 20;12(10):2085-90.
67. [The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer's disease](#). Kraszpulski M, Soininen H, Helisalmi S, **Alafuzoff I**. Acta Neurol Scand. 2001 Feb;103(2):88-92.
66. [Auditory event-related potentials differentiate patients with normal pressure hydrocephalus and patients with concomitant Alzheimer's disease verified by brain biopsy](#). **Savolainen S**, Karhu J, Pääkkönen A, Paljärvi L, Partanen J, **Alafuzoff I**, Vapalahti M. Neuroreport. 2001 Jan 22;12(1):33-7.

2000

65. [MPO and APOE epsilon4 polymorphisms interact to increase risk for AD in Finnish males](#). Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, **Alafuzoff I**, Soininen H. Neurology. 2000 Nov 14;55(9):1284-90.
64. [DNA fragmentation, gliosis and histological hallmarks of Alzheimer's disease](#). Overmyer M, Kraszpulski M, Helisalmi S, Soininen H, **Alafuzoff I**. Acta Neuropathol. 2000 Dec;100(6):681-7.
63. [Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer's disease family: an Alu core sequence-stimulated recombination?](#) Hiltunen M, Helisalmi S, Mannermaa A, **Alafuzoff I**, Koivisto AM, Lehtovirta M, Pirskanen M, Sulkava R, Verkkoniemi A, Soininen H. Eur J Hum Genet. 2000 Apr;8(4):259-66.
62. [Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia](#). **Alafuzoff I**, Helisalmi S, Mannermaa A, Soininen H. Ann N Y Acad Sci. 2000 Apr;903:244-51.

61. [Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease.](#) **Alafuzoff I**, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H, Koivisto K. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):815-9.

60. [Morphology of spiny neurons in the human entorhinal cortex: intracellular filling with lucifer yellow.](#) Mikkonen M, Pitkänen A, Soininen H, **Alafuzoff I**, Miettinen R. Neuroscience. 2000;96(3):515-22.

59. [MR imaging of the hippocampus in normal pressure hydrocephalus: correlations with cortical Alzheimer's disease confirmed by pathologic analysis.](#) Savolainen S, Laakso MP, Paljärvi L, **Alafuzoff I**, Hurskainen H, Partanen K, Soininen H, Vapalahti M. AJNR Am J Neuroradiol. 2000 Feb;21(2):409-14.

58. [Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.](#) Tapiola T, Pirttilä T, Mikkonen M, Mehta PD, **Alafuzoff I**, Koivisto K, Soininen H. Neurosci Lett. 2000 Feb 18;280(2):119-22.

57. [Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease?](#) Helisalmi S, Hiltunen M, Mannermaa A, Koivisto AM, Lehtovirta M, **Alafuzoff I**, Ryyänänen M, Soininen H. Neurosci Lett. 2000 Jan 7;278(1-2):65-8.

1999

56. [A case of sudden death caused by fibromuscular dysplasia.](#) Ropponen KM, **Alafuzoff I**. J Clin Pathol. 1999 Jul;52(7):541-2.

55. [Upregulated expression of Fas and Fas ligand in brain through the spectrum of HIV-1 infection.](#) Elovaara I, Sabri F, Gray F, **Alafuzoff I**, Chiodi F. Acta Neuropathol. 1999 Oct;98(4):355-62.

54. [Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer's disease.](#) Mikkonen M, **Alafuzoff I**, Tapiola T, Soininen H, Miettinen R. Neuroscience. 1999;92(2):515-32.

53. [Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue.](#) Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P Sr, **Alafuzoff I**. Dement Geriatr Cogn Disord. 1999 Jul-Aug;10(4):252-7.

52. [Rapidly progressive multifocal leukoencephalopathy with substantial cell-mediated inflammatory response and with cognitive decline of non-Alzheimer type in a 75-year-old female patient.](#) **Alafuzoff I**, Hartikainen P, Hanninen T, Partanen K, Kuikka J, Syrjänen K, Naukkarinen A, Soininen H. Clin Neuropathol. 1999 May-Jun;18(3):113-23.

51. [Hippocampal plasticity in Alzheimer's disease: changes in highly polysialylated NCAM immunoreactivity in the hippocampal formation.](#) Mikkonen M, Soininen H, Tapiola T, **Alafuzoff I**, Miettinen R. Eur J Neurosci. 1999 May;11(5):1754-64.

50. [Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue.](#) Overmyer M, Helisalmi S, Soininen H, Laakso M, Riekkinen P Sr, **Alafuzoff I**. Acta Neuropathol. 1999 Apr;97(4):383-92.

1998

49. [Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in human brain tissue.](#)

Kraszpulski M, Soininen H, Riekkinen P Sr, **Alafuzoff I**. Histochem Cell Biol. 1998 Oct;110(4):439-45.

48. [Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease.](#)

Tapiola T, Lehtovirta M, Pirttilä T, **Alafuzoff I**, Riekkinen P, Soininen H. Lancet. 1998 Jul 25;352(9124):287. No abstract available.

1997

47. [The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease.](#)

Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, **Alafuzoff I**, Riekkinen P Sr, Soininen H. Neuroreport. 1997 Dec 22;8(18):3961-3.

1996

46. [Intact brain serotonin system in vascular dementia.](#) Hansson G, **Alafuzoff I**, Winblad B, Marcusson J. Dementia. 1996 Jul-Aug;7(4):196-200.

45. [Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.](#)

Blennow K, Bogdanovic N, **Alafuzoff I**, Ekman R, Davidsson P. J Neural Transm. 1996;103(5):603-18.

1994

44. [A retrospective analysis of clinical diagnoses and autopsy findings in 3,042 cases during two different time periods.](#) Veress B, **Alafuzoff I**. Hum Pathol. 1994 Feb;25(2):140-5.

43. [A comparison of multiplex and simplex families with Alzheimer's disease/senile dementia of Alzheimer type within a well defined population.](#) **Alafuzoff I**, Almqvist E, Adolfsson R,

Lake S, Wallace W, Greenberg DA, Winblad B. J Neural Transm Park Dis Dement Sect. 1994;7(1):61-72.

1993

42. [The selection for post-mortem examination: a retrospective analysis of 74 deceased surgical cases.](#) **Alafuzoff I**, Veress B. Qual Assur Health Care. 1993 Dec;5(4):345-9.

41. [Clinical diagnostic accuracy audited by autopsy in a university hospital in two eras.](#)

Veress B, **Alafuzoff I**. Qual Assur Health Care. 1993 Dec;5(4):281-6.

40. [Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy](#). Seiger A, Nordberg A, von Holst H, Bäckman L, Ebendal T, **Alafuzoff I**, Amberla K, Hartvig P, Herlitz A, Lilja A, et al. Behav Brain Res. 1993 Nov 30;57(2):255-61.

39. [Coupling of muscarinic receptors to GTP proteins in postmortem human brain--alterations in Alzheimer's disease](#). Warpman U, **Alafuzoff I**, Nordberg A. Neurosci Lett. 1993 Feb 5;150(1):39-43.

38. [How to run a brain bank: potentials and pitfalls in the use of human post-mortem brain material in research](#). **Alafuzoff I**, Winblad B. J Neural Transm Suppl. 1993;39:235-43.

1992

37. [Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists](#). Svensson AL, **Alafuzoff I**, Nordberg A. Brain Res. 1992 Nov 20;596(1-2):142-8.

36. [Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type](#). Söderberg M, Edlund C, **Alafuzoff I**, Kristensson K, Dallner G. J Neurochem. 1992 Nov;59(5):1646-53.

35. [Adenylyl cyclase activity in postmortem human brain: evidence of altered G protein mediation in Alzheimer's disease](#). Cowburn RF, O'Neill C, Ravid R, **Alafuzoff I**, Winblad B, Fowler CJ. J Neurochem. 1992 Apr;58(4):1409-19.

34. [Brain gamma-aminobutyrate aminotransferase \(GABA-T\) and monoamine oxidase \(MAO\) in patients with Alzheimer's disease](#). Sherif F, Gottfries CG, **Alafuzoff I**, Oreland L. J Neural Transm Park Dis Dement Sect. 1992;4(3):227-40.

33. [Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia](#). Nordberg A, **Alafuzoff I**, Winblad B. J Neurosci Res. 1992 Jan;31(1):103-11.

32. [Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient \(case report\)](#). Olson L, Nordberg A, von Holst H, Bäckman L, Ebendal T, **Alafuzoff I**, Amberla K, Hartvig P, Herlitz A, Lilja A, et al. J Neural Transm Park Dis Dement Sect. 1992;4(1):79-95.

31. [The pathology of dementias: an overview](#). **Alafuzoff I**. Acta Neurol Scand Suppl. 1992;139:8-15. Review. No abstract available.

30. [Neurotransmitter-mediated inhibition of post-mortem human brain adenylyl cyclase](#). Garlind A, Fowler CJ, **Alafuzoff I**, Winblad B, Cowburn RF. J Neural Transm Gen Sect. 1992;87(2):113-24.

29. [Preservation of 5-hydroxytryptamine 1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease](#).

O'Neill C, Cowburn RF, Wiehager B, **Alafuzoff I**, Winblad B, Fowler CJ. Neurosci Lett. 1991 Nov 25;133(1):15-9.

28. [Coupling of human brain cerebral cortical alpha 2-adrenoceptors to GTP-binding proteins in Alzheimer's disease.](#) O'Neill C, Fowler CJ, Wiehager B, Cowburn RF, **Alafuzoff I**, Winblad B. Brain Res. 1991 Nov 1;563(1-2):39-43.

27. [Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment.](#) Nordstedt C, Gandy SE, **Alafuzoff I**, Caporaso GL, Iverfeldt K, Grebb JA, Winblad B, Greengard P. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8910-4.

26. [Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain.](#) Bergström L, Garlind A, Nilsson L, **Alafuzoff I**, Fowler CJ, Winblad B, Cowburn RF. J Neurol Sci. 1991 Oct;105(2):225-33.

25. [Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease.](#)

Cowburn RF, Fowler CJ, Garlind A, **Alafuzoff I**, Nilsson L, Winblad B, Bergström L. J Neurol Neurosurg Psychiatry. 1991 Aug;54(8):748-9. No abstract available.

24. [Granulomatous peritonitis and appendicitis of food starch origin.](#) Veress B, **Alafuzoff I**, Juliusson G. Gut. 1991 Jun;32(6):718-20.

23. [\[High frequency of autopsies at regional centers is desirable\].](#) Veress B, **Alafuzoff I**. Lakartidningen. 1991 May 15;88(20):1876-9. Swedish. No abstract available.

22. [Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain.](#) O'Neill C, Fowler CJ, Wiehager B, **Alafuzoff I**, Winblad B. Brain Res. 1991 Mar 15;543(2):307-14.

21. [Characterization and quantification of \(125\)I-bolton hunter substance P binding sites in human brain.](#) Nilsson L, Winblad B, Volkmann I, **Alafuzoff I**, Bergström L. Neurochem Int. 1991;18(3):399-404.

20. [Characterization and regional distribution of adenylyl cyclase activity from human brain.](#) Cowburn RF, Garlind A, O'Neill C, **Alafuzoff I**, Winblad B, Fowler CJ. Neurochem Int. 1991;18(3):389-98.

1990

19. [Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue.](#) Nilsson E, **Alafuzoff I**, Blennow K, Blomgren K, Hall CM, Janson I, Karlsson I, Wallin A, Gottfries CG, Karlsson JO. Neurobiol Aging. 1990 Jul-Aug;11(4):425-31.

18. [New approaches to clinical and postmortem investigations of cholinergic mechanisms.](#) Nordberg A, Adem A, Nilsson-Håkansson L, Bucht G, Hartvig P, **Alafuzoff I**, Viitanen M, Långström B, Winblad B. Prog Brain Res. 1990;84:313-20. Review. No abstract available.

17. [Loss of dopamine uptake sites labeled with \[3H\]GBR-12935 in Alzheimer's disease.](#) Allard P, **Alafuzoff I**, Carlsson A, Eriksson K, Ericson E, Gottfries CG, Marcusson JO. Eur Neurol. 1990;30(4):181-5.

1989

16. [Neurotransmitter deficits in a non-multi-infarct category of vascular dementia.](#) Wallin A, **Alafuzoff I**, Carlsson A, Eckernäs SA, Gottfries CG, Karlsson I, Svennerholm L, Winblad B. Acta Neurol Scand. 1989 May;79(5):397-406.

15. [The role of nicotinic receptors in the pathophysiology of Alzheimer's disease.](#) Nordberg A, Nilsson-Håkansson L, Adem A, Hardy J, **Alafuzoff I**, Lai Z, Herrera-Marschitz M, Winblad B. Prog Brain Res. 1989;79:353-62. Review. No abstract available.

14. [Histopathological classification of dementias by multivariate data analysis.](#) **Alafuzoff I**, Iqbal K, Friden H, Adolfsson R, Winblad B. Prog Clin Biol Res. 1989;317:295-301.

1988

13. [Nutritional status in patients with acute stroke.](#) Axelsson K, Asplund K, Norberg A, **Alafuzoff I**. Acta Med Scand. 1988;224(3):217-24.

1987

12. [5-Hydroxytryptamine-sensitive \[3H\]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders.](#) Marcusson JO, **Alafuzoff I**, Bäckström IT, Ericson E, Gottfries CG, Winblad B. Brain Res. 1987 Nov 3;425(1):137-45.

11. [Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis.](#) **Alafuzoff I**, Iqbal K, Friden H, Adolfsson R, Winblad B. Acta Neuropathol. 1987;74(3):209-25.

10. [Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study.](#) **Alafuzoff I**, Adolfsson R, Grundke-Iqbal I, Winblad B. Acta Neuropathol. 1987;73(2):160-6.

1986

9. [Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type.](#) Nordberg A, **Alafuzoff I**, Winblad B. Neurosci Lett. 1986 Sep 25;70(1):160-4.

8. [Defective brain microtubule assembly in Alzheimer's disease.](#) Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, Wisniewski HM, **Alafuzoff I**, Winblad B. Lancet. 1986 Aug 23;2(8504):421-6. Erratum in: Lancet 1986 Nov 15;2(8516):1174.

7. [Isoelectric focusing and two-dimensional gel electrophoresis in plasma and cerebrospinal fluid from patients with dementia.](#) **Alafuzoff I**, Adolfsson R, Bucht G, Jellum E, Mehta PD, Winblad B. Eur Neurol. 1986;25(4):285-9.

1985

6. [Transmitter deficits in Alzheimer's disease.](#) Hardy J, Adolfsson R, **Alafuzoff I**, Bucht G, Marcusson J, Nyberg P, Perdahl E, Wester P, Winblad B. Neurochem Int. 1985;7(4):545-63.

5. [Perivascular deposits of serum proteins in cerebral cortex in vascular dementia.](#) **Alafuzoff I**, Adolfsson R, Grundke-Iqbal I, Winblad B. Acta Neuropathol. 1985;66(4):292-98.

1984

4. [Blood components in an elderly population.](#) Osterlind PO, **Alafuzoff I**, Löfgren AC, Marklund S, Nyström L, Sandman PO, Steen B, Winblad B. Gerontology. 1984;30(4):247-52.

3. [Synapsin I \(protein I\) in different brain regions in senile dementia of Alzheimer type and in multi-infarct dementia.](#) Perdahl E, Adolfsson R, **Alafuzoff I**, Albert KA, Nestler EJ, Greengard P, Winblad B. J Neural Transm. 1984;60(2):133-41.

1983

2. [Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia.](#) **Alafuzoff I**, Adolfsson R, Bucht G, Winblad B. J Neurol Sci. 1983 Aug-Sep;60(3):465-72.

1. [Muscarinic receptor compensation in hippocampus of Alzheimer patients.](#) Nordberg A, Larsson C, Adolfsson R, **Alafuzoff I**, Winblad B. J Neural Transm. 1983;56(1):13-9.